Core Scientific Inc vs Zoetis Inc — how do they compare? Core Scientific Inc trades at $15.29 (market cap $4.94B), while Zoetis Inc trades at $74.36 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 6.1× Core Scientific Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Zoetis Inc for 70 Days on average.
| CORZ | ZTS | |
|---|---|---|
Market Cap | $4.94B | $30.20B |
Volume | 15,630,800 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $29.16 | $147.53 |
52-Week Low | $13.57 | $69.09 |
Typical Hold Time | 20 Days | 70 Days |
Enterprise Value | $7.46B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.30, down 4.02% today amid bearish technical signals and negative earnings momentum. The stock faces fundamental challenges with a net income margin of -324.9% and three consecutive quarterly earnings misses. However, analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.75 consensus price target, while recent executive appointments and AI infrastructure developments provide potential catalysts.
Despite current financial struggles, CORZ shows potential through its pivot to AI data center services and strong institutional support. Key risks include persistent negative profitability, high capital expenditures, and cryptocurrency market volatility. The significant gap between current price and analyst targets suggests upside potential if the company executes its AI infrastructure strategy successfully.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →